Payment overview · 2025
General Payments
$89,966.40
201 reported records · 26 companies
Healthcare provider profile · identity verified
Malcolm Foster, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · KNOXVILLE, TN · NPI 1861482556
Verified facts
What the public records show
CMS Open Payments records show Malcolm Foster, M.D. received $89,966.40 in general payments during 2025 across 201 reported records.
Penumbra, Inc. accounted for 35.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 284 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 284 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $32,112.12 | 35.7% | 34 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $30,931.79 | 34.4% | 29 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24,735.33 | 27.5% | 38 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $435.55 | 0.5% | 23 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $399.10 | 0.4% | 15 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $345.16 | 0.4% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $171.33 | 0.2% | 13 | 2025 |
| Ancora Heart, Inc. | Unresolved — no canonical attribution shown | $107.71 | 0.1% | 7 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $98.89 | 0.1% | 3 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $68.55 | 0.1% | 4 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $64.50 | 0.1% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $56.31 | 0.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.21 | 0.1% | 3 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $45.39 | 0.1% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $42.02 | 0.1% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$41.20 | 0.1% | 2 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $40.61 | 0.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $40.00 | 0.0% | 2 | 2025 |
| Endovascular Engineering Inc. | Unresolved — no canonical attribution shown | $33.12 | 0.0% | 3 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $29.77 | 0.0% | 1 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $27.30 | 0.0% | 1 | 2025 |
| Thrombolex, Inc. | Unresolved — no canonical attribution shown | $25.70 | 0.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.75 | 0.0% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $15.35 | 0.0% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $14.94 | 0.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.70 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $37,250.00 | 10 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $23,800.00 | 5 |
| Travel and Lodging | $14,316.31 | 31 |
| Food and Beverage | $7,400.09 | 154 |
| Compensation for serving as faculty or as a speaker for a medical education program | $7,200.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $30,931.79 | 29 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $25,268.03 | 28 | 2025 |
Source payment records
|
|||||
| XACT Normalized: xact |
Device | Abbott Laboratories | $14,723.47 | 30 | 2025 |
Source payment records
|
|||||
| OPTIS Normalized: optis |
Device | Abbott Laboratories | $9,000.00 | 1 | 2025 |
Source payment records
|
|||||
| RUBY Coil Normalized: ruby coil |
Device | Penumbra, Inc. | $6,844.09 | 6 | 2025 |
Source payment records
|
|||||
| AMPLATZER TALISMAN Normalized: amplatzer talisman |
Device | Abbott Laboratories | $470.61 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $435.55 | 23 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $345.16 | 7 | 2025 |
Source payment records
|
|||||
| ACCULINK Normalized: acculink |
Device | Abbott Laboratories | $338.65 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $171.33 | 13 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $160.41 | 11 | 2025 |
Source payment records
|
|||||
| THORATEC HEARTMATE 3 LVAS IMPLANT KIT Normalized: thoratec heartmate 3 lvas implant kit |
Device | Abbott Laboratories | $148.36 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $120.03 | 1 | 2025 |
Source payment records
|
|||||
| AccuCinch Normalized: accucinch |
Device | Ancora Heart, Inc. | $107.71 | 7 | 2025 |
Source payment records
|
|||||
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $98.89 | 3 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $68.55 | 4 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $64.50 | 3 | 2025 |
Source payment records
|
|||||
| SYNERGY Normalized: synergy |
Device | Boston Scientific Corporation | $64.03 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $56.31 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $49.21 | 3 | 2025 |
Source payment records
|
|||||
| AMPLATZER AMULET Normalized: amplatzer amulet |
Device | Abbott Laboratories | $45.47 | 2 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE MVP XL VVCS 10-12F Normalized: cardiva vascade mvp xl vvcs 10 12f |
Device | CARDIVA MEDICAL, INC. | $45.39 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $42.02 | 2 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $40.61 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $40.00 | 2 | 2025 |
Source payment records
|
|||||
| Helo Thrombectomy System Normalized: helo thrombectomy system |
Device | Endovascular Engineering Inc. | $33.12 | 3 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $29.77 | 1 | 2025 |
Source payment records
|
|||||
| General - Structural Heart Normalized: general structural heart |
Device | Boston Scientific Corporation | $27.65 | 1 | 2025 |
Source payment records
|
|||||
| ALPHAVAC Normalized: alphavac |
Device | AngioDynamics, Inc. | $27.30 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $26.98 | 1 | 2025 |
Source payment records
|
|||||
| Bashir Endovascular Catheter Normalized: bashir endovascular catheter |
Device | Thrombolex, Inc. | $25.70 | 1 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $25.06 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| PROTEGE RX Normalized: protege rx |
Device | Medtronic, Inc. | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| Coronary Other Normalized: coronary other |
Device | Philips North America LLC | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.70 | 1 | 2025 |
Source payment records
|
|||||
| XIENCE SKYPOINT Normalized: xience skypoint |
Device | Abbott Laboratories | $8.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 284 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
79 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
284 | 85 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
79 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
284 | 85 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 478 | 170 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 340 | 113 |
| Atorvastatin Calcium | Atorvastatin Calcium | 309 | 102 |
| Eliquis | Apixaban | 284 | 85 |
| Repatha Sureclick | Evolocumab | 234 | 51 |
| Losartan Potassium | Losartan Potassium | 203 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 195 | 59 |
| Ezetimibe | Ezetimibe | 182 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 156 | 53 |
| Xarelto | Rivaroxaban | 154 | 38 |
| Carvedilol | Carvedilol | 151 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 135 | 34 |
| Prasugrel Hcl | Prasugrel Hcl | 101 | 29 |
| Brilinta | Ticagrelor | 79 | 26 |
| Entresto | Sacubitril/Valsartan | 79 | 19 |
| Lisinopril | Lisinopril | 79 | 26 |
| Spironolactone | Spironolactone | 65 | 28 |
| Furosemide | Furosemide | 63 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 59 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 17 |
| Nitroglycerin | Nitroglycerin | 53 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 47 | 17 |
| Sotalol | Sotalol Hcl | 46 | 15 |
| Simvastatin | Simvastatin | 45 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 12 |
| Flecainide Acetate | Flecainide Acetate | 34 | suppressed |
| Potassium Chloride | Potassium Chloride | 34 | 13 |
| Praluent Pen | Alirocumab | 32 | suppressed |
| Dofetilide | Dofetilide | 30 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Ranolazine Er | Ranolazine | 23 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Eplerenone | Eplerenone | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Omeprazole | Omeprazole | 13 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $89,966.40 · 201 records | Penumbra, Inc. | ACCULINK, ALPHAVAC, AMPLATZER AMULET, AMPLATZER TALISMAN, AccuCinch, Barostim Neo System, Bashir Endovascular Catheter, CAMZYOS, CARDIVA VASCADE MVP XL VVCS 10-12F, CARTO 3, Coronary Other, ELIQUIS, EVKEEZA, FARXIGA, FFRct, FUROSCIX, General - Structural Heart, HAWKONE, Helo Thrombectomy System, Indigo System, Kerendia, LEQVIO, LifeVest, NEXLETOL, OPTIS, Ozempic, PROTEGE RX, REPATHA, RUBY Coil, SYNERGY, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, WATCHMAN, WATCHMAN Access System, WATCHMAN FLX, XACT, XIENCE SKYPOINT | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error